Postprandial Glycemia, Insulin Resistance
Conditions
Keywords
chestnuts, postprandial glycemia, postprandial insulinemia, glucose tolerance
Brief summary
Nut consumption is known to improve health outcomes, such as reducing the risk of chronic diseases like diabetes, cognitive impairment, and cardiovascular diseases. While most research has focused on walnuts and almonds, there is limited information on the health benefits of chestnuts. Chestnuts are unique among tree nuts due to their high starch and fibre content, along with vitamins E and C, minerals (potassium, phosphorus, magnesium), and polyphenols. Evidence from in vitro and animal studies suggests that chestnuts may positively affect health by regulating the gut microbiome, lowering the glycaemic index, and providing antioxidant benefits. The food industry is also exploring new uses for chestnuts, particularly in gluten-free products, due to their nutritional benefits and good taste. Nonetheless, no research has investigated the health effects of chestnuts in humans. By addressing this gap in the literature, the study may lead to the development of new dietary strategies for improved health outcomes.
Interventions
OTHERChestnut meal
Participants will receive an isocaloric baked meal with chestnut flour.
OTHERControl meal
Participants will receive an isocaloric baked meal without chestnut flour.
Sponsors
Monash University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
SINGLE (Subject)
Intervention model description
The participants will be requested to attend 2 morning visits to the research centre to receive one of the test meals. These meals will be isocaloric with or without the addition of chestnut flour. The order in which they undertake the two test visits will be randomised.
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Adults 18-65 years old * Available to attend two testing sessions at the research facility
Exclusion criteria
* Allergy to nuts and/or gluten, * BMI\<18.5 or ≥30 kg/m2, * Fasting glucose \>5.6 mmol/L, presence of diabetes and/or taking anti-diabetic medication * Serious health conditions that may affect participation e.g. liver or thyroid dysfunction, recent major surgery, * Smoker, * Cardiovascular disease * Pregnant or breastfeeding women * Presence of implanted cardiac defibrillator
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Postprandial blood glucose incremental area under the curve (iAUC) | Three hour blood glucose iAUC will be calculated from nine time points (0, 15, 30, 45, 60, 90, 120, 150 and 180 mins) after beginning consumption of the test meal. | Difference in postprandial blood glucose iAUC |
| Postprandial plasma insulin incremental area under the curve (iAUC) | Three hour insulin iAUC will be calculated from seven time points (0, 30, 60, 90, 120, 150 and 180 mins) after beginning consumption of the test meal. | Difference in postprandial plasma insulin iAUC. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Postprandial glucose concentration | Glucose concentration will be measured at nine time points (0, 15, 30, 45, 60, 90, 120, 150 and 180 mins) after beginning consumption of the test meal. | Difference in postprandial glucose concentration |
| Postprandial insulin concentration | Insulin concentration will be measured in finger prick blood samples at seven time points (0, 30, 60, 90, 120, 150 and 180 mins) after beginning consumption of the test meal. | Difference in postprandial insulin concentration |
| Time to peak glucose | Three hours | Difference in time to peak glucose |
Countries
Australia
Outcome results
None listed